Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
New Science Ventures, LLC (NSV) is a venture capital firm founded in 2004 and headquartered in Connecticut, with an additional office in London. The firm focuses on investing in companies that leverage scientific innovations to address significant market needs, particularly in the life sciences and information technology sectors. NSV manages over $900 million in assets across more than 80 portfolio companies, with a geographic reach that includes the United States, Europe, India, and China.
Since its inception, NSV has evolved to become a key player in the venture capital landscape, emphasizing investments in early and late-stage companies. The firm has established a strong reputation for its deep scientific expertise and board-level support, which it provides to its portfolio companies. Notable milestones include successful exits such as Biovex, acquired by Amgen, and Akarna Therapeutics, acquired by Allergan. NSV continues to actively engage with its portfolio, sharing updates and insights through various channels.
New Science Ventures invests across multiple stages, including seed, Series A, Series B, Series C, and growth equity. The firm targets companies within the life sciences and information technology sectors, emphasizing those that address large global markets and possess differentiated value propositions. NSV seeks to invest in areas with strong long-term growth potential, including high-performance semiconductors, cellular infrastructure, data analytics, therapeutics, and medical devices across various clinical indications.
The firm looks for strong management teams capable of executing their vision and addressing significant market needs. NSV's investment strategy is designed to identify companies that not only have innovative technologies but also demonstrate the potential for substantial market impact. Their cross-border investment capabilities enhance their ability to support companies in both the US and Europe, allowing for a broader strategic approach to growth.
New Science Ventures has a diverse portfolio of over 80 companies, with notable investments across various sectors. Key portfolio companies include:
These companies exemplify NSV's commitment to investing in innovative solutions that address significant market needs in life sciences and information technology.
Somu Subramaniam: Managing Partner with extensive experience in venture capital and a background in life sciences.
Tom Lavin: Partner who specializes in technology investments, particularly in information technology and semiconductors.
Jean-Pierre Bizet: Partner and Senior Advisor with a focus on strategic guidance and operational support for portfolio companies.
Raju Mohan: Partner and Senior Advisor with expertise in healthcare investments and market strategy.
Andrew Abrams: Partner with a strong background in venture capital and technology commercialization.
Brenda Marex: Partner and Chief Financial Officer, responsible for financial strategy and operations.
Matt Crotty: Controller overseeing financial reporting and compliance.
To pitch New Science Ventures, founders should use the contact form available on their website at newscienceventures.com. It is important to include a comprehensive deck that outlines the business model, market analysis, and team qualifications. NSV prefers warm introductions but will also consider direct submissions through their website.
Response times may vary, but founders can expect to hear back within a few weeks of submission.
In early 2026, New Science Ventures has been actively sharing updates about their portfolio companies through blog posts. Topics include regulatory milestones achieved by portfolio companies, partnerships in semiconductor technology, and advancements in clinical research.
Notable recent activity includes Ventyx Biosciences raising $114 million to further develop its immunology platform, showcasing NSV's commitment to supporting innovative companies in the life sciences sector.
What are New Science Ventures' investment criteria?
NSV invests in early and late-stage companies within the life sciences and information technology sectors. They focus on companies that address large global markets, possess differentiated value propositions, and have strong management teams.
How can I apply or pitch to New Science Ventures?
Founders can pitch their ideas through the NSV website at newscienceventures.com. It is advisable to include a detailed business plan and information about the management team.
What makes New Science Ventures different from other VC firms?
NSV emphasizes scientific innovation and has a strong focus on life sciences and information technology. Their deep scientific expertise and board-level support provide significant value to portfolio companies.
What is the geographic scope of New Science Ventures?
NSV invests primarily in North America and Europe, but they also have a presence in India and China, allowing for cross-border investment opportunities.
What is the typical fund size and check size for investments?
NSV manages over $900 million in assets and invests across various stages, including seed, Series A, Series B, Series C, and growth equity. Specific check sizes may vary based on the stage and needs of the company.
What kind of post-investment involvement does New Science Ventures have?
NSV provides deep scientific and board expertise to its portfolio companies, facilitating growth and innovation. They actively engage with their companies to support their development and strategic direction.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.